729 related articles for article (PubMed ID: 16682719)
21. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
Tuffaha HW; Treish IM; Zaru L
J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
[TBL] [Abstract][Full Text] [Related]
22. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
[TBL] [Abstract][Full Text] [Related]
23. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
Gridelli C; Aapro MS; Barni S; Beretta GD; Colucci G; Daniele B; Del Mastro L; Di Maio M; De Petris L; Perrone F; Thatcher N; De Marinis F
Crit Rev Oncol Hematol; 2007 Jul; 63(1):53-64. PubMed ID: 17368037
[TBL] [Abstract][Full Text] [Related]
24. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
Lyman GH; Kleiner JM
Cancer Treat Res; 2011; 157():145-65. PubMed ID: 21052955
[TBL] [Abstract][Full Text] [Related]
25. Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis.
Pettengell R; Schwenkglenks M; Bacon P; Lawrinson S; Duehrsen U
Hematol Oncol; 2011 Dec; 29(4):177-84. PubMed ID: 21246591
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.
Saloustros E; Tryfonidis K; Georgoulias V
Expert Opin Pharmacother; 2011 Apr; 12(6):851-63. PubMed ID: 21254862
[TBL] [Abstract][Full Text] [Related]
27. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
[TBL] [Abstract][Full Text] [Related]
28. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
[TBL] [Abstract][Full Text] [Related]
29. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
Kuderer NM; Dale DC; Crawford J; Lyman GH
J Clin Oncol; 2007 Jul; 25(21):3158-67. PubMed ID: 17634496
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
31. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
32. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
33. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
34. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
Watanabe T
Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
[TBL] [Abstract][Full Text] [Related]
35. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
36. First-Cycle CSF use in breast cancer and NHL: guidelines and recommendations.
Al-Kali A; Ozer H
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):7-12. PubMed ID: 17370923
[TBL] [Abstract][Full Text] [Related]
37. Evidence-based use of colony-stimulating factors in elderly cancer patients.
Lyman GH; Kuderer N; Agboola O; Balducci L
Cancer Control; 2003; 10(6):487-99. PubMed ID: 14652525
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
39. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Weeks JA; Somerfield MR; Feinglass J; Smith TJ
J Clin Oncol; 1999 Nov; 17(11):3676-81. PubMed ID: 10550166
[TBL] [Abstract][Full Text] [Related]
40. Risk assessment in oncology clinical practice. From risk factors to risk models.
Lyman GH
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):8-13. PubMed ID: 14682113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
